Featured Publications
Factors influencing the decision to receive seasonal influenza vaccination among US corporate non-healthcare workers
Aguolu OG, Willebrand K, Elharake JA, Qureshi HM, Kiti MC, Liu CY, Mesa A, Nelson K, Jenness S, Melegaro A, Ahmed F, Yildirim I, Malik FA, Lopman B, Omer SB. Factors influencing the decision to receive seasonal influenza vaccination among US corporate non-healthcare workers. Human Vaccines & Immunotherapeutics 2022, 18: 2122379. PMID: 36136345, PMCID: PMC9746537, DOI: 10.1080/21645515.2022.2122379.Peer-Reviewed Original ResearchConceptsInfluenza vaccinationNon-healthcare workersInfluenza vaccinePromotion messagesWorkplace vaccination programsSeasonal influenza vaccinationInfluenza vaccine acceptancePublic health authoritiesLogistic regression modelsInfluenza seasonPhysician recommendationVaccination acceptanceVaccine accessibilityVaccine acceptanceSevere outcomesVaccination programPromotion interventionsUS adultsWork absenceVaccinationVaccination decisionsHealth authoritiesSignificant mortalityUnderstanding predictorsSignificant predictors
2021
Serotype Distribution of Remaining Pneumococcal Meningitis in the Mature PCV10/13 Period: Findings from the PSERENADE Project
Garcia Quesada M, Yang Y, Bennett JC, Hayford K, Zeger SL, Feikin DR, Peterson ME, Cohen AL, Almeida SCG, Ampofo K, Ang M, Bar-Zeev N, Bruce MG, Camilli R, Chanto Chacón G, Ciruela P, Cohen C, Corcoran M, Dagan R, De Wals P, Desmet S, Diawara I, Gierke R, Guevara M, Hammitt LL, Hilty M, Ho PL, Jayasinghe S, Kleynhans J, Kristinsson KG, Ladhani SN, McGeer A, Mwenda JM, Nuorti JP, Oishi K, Ricketson LJ, Sanz JC, Savrasova L, Setchanova LP, Smith A, Valentiner-Branth P, Valenzuela MT, van der Linden M, van Sorge NM, Varon E, Winje BA, Yildirim I, Zintgraff J, Knoll MD, . Serotype Distribution of Remaining Pneumococcal Meningitis in the Mature PCV10/13 Period: Findings from the PSERENADE Project. Microorganisms 2021, 9: 738. PMID: 33916227, PMCID: PMC8066874, DOI: 10.3390/microorganisms9040738.Peer-Reviewed Original ResearchHigher-valency PCVsPneumococcal meningitisSerotype distributionPneumococcal meningitis incidencePneumococcal serotype replacementAfrican meningitis beltPneumococcal meningitis casesYears of agePCV13 typesSerotype replacementMeningitis casesVaccine introductionMeningitis beltMeningitis incidenceVaccination programInvestigational productMeningitisSerotype 3SerotypesPCVRegression modelsAgeYearsPCV10/13PCV10
2020
Herd Immunity and Implications for SARS-CoV-2 Control
Omer SB, Yildirim I, Forman HP. Herd Immunity and Implications for SARS-CoV-2 Control. JAMA 2020, 324: 2095-2096. PMID: 33074293, DOI: 10.1001/jama.2020.20892.Peer-Reviewed Original Research
2007
Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005
Ceyhan M, Yildirim I, Balmer P, Riley C, Laher G, Andrews N, Borrow R, Kurt N, Turgut M, Aydogan A, Ecevit C, Uysal G, Schultze V. Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005. Vaccine 2007, 25: 7233-7237. PMID: 17707957, DOI: 10.1016/j.vaccine.2007.07.019.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAgedAged, 80 and overAntibodies, BacterialChildChild, PreschoolFemaleHumansImmunoglobulin GInfantInfant, NewbornMaleMeningococcal InfectionsMicrobial ViabilityMiddle AgedNeisseria meningitidis, Serogroup ANeisseria meningitidis, Serogroup CNeisseria meningitidis, Serogroup W-135Neisseria meningitidis, Serogroup YSeroepidemiologic StudiesTurkeyConceptsSerum bactericidal antibodySerogroups ASerogroup CIgG concentrationsMeningococcal serogroup C diseaseSerum bactericidal antibody activityTurkish populationMeningococcal serogroup CMeningococcal vaccination programsSerogroup C diseaseAge-specific seroprevalenceSpecific IgG concentrationsRates of susceptibilityBactericidal antibody activityBaseline seroprevalenceSBA titersAntibody levelsProtective antibodiesIgG antibodiesVaccination programBactericidal antibodiesHealth centersC diseaseStudy populationC meningococci